Daniel Epstein
Angel Investor @ Unreasonable
Daniel Epstein is a Series D investor at Unreasonable focused on Medical and Oncology.
- Total investments:
- 1
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Daniel Epstein invests in
Stages Daniel Epstein invests in
Countries Daniel Epstein invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Medical 1 (100%)
- Oncology 1 (100%)
- Biotechnology 1 (100%)
- Machine Learning 1 (100%)
- Health Diagnostics 1 (100%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Icaria's mission is to create a new society in which people will not lose their lives by using urine tests to provide "early, painless and accurate early diagnosis of cancer."It is known that detecting cancer early increases the survival rate 5 to 10 times and greatly improves the prognosis. However, it is not unusual for manycancers to have no subjective symptoms, and when they become aware they have progressed to a stage where treatment is impossible. The most effective way to detect cancer at an early stage that can be treated is to have regular and high-precision cancer diagnosis, but existing cancer diagnosis is painful and However, many of them are not accurate enough and are not suitable for regular diagnosis and early stage diagnosis. | $24.4M / Series D / Aug 18, 2026 |
Co-Investors
Granite-Integral
1 deal together
Hokkaido Co-Creation Partners
1 deal together
Kodomo no Mori
1 deal together
TAUNS Laboratories
1 deal together
X&KSK
1 deal together
About Unreasonable
Unreasonable exists to re-purpose capitalism. We are an international company that supports a Fellowship for growth-stage entrepreneurs, channels exclusive deal-flow to investors, and partners with institutions to discover profit in solving global problems.The 249 ventures in the Unreasonable Fellowship operate across more than 180 countries,have collectively generated $3.6 billion in revenue, raised $4.7 billion in financing, and are positively impacting the lives of more than 530 million people.
Unreasonable Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Krating Poonpol
Founding Member
|
|||
Neeta Rastogi Singh
CFO / COO
|
|||
Bhanu Potta
Unreasonable Mentor
|
|||
Brendan Richardson
Unreasonable Fellow
|
|||
Christiana Wyly
Chairwoman, Board Of Directors
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Daniel Epstein invest in?
Daniel Epstein invests primarily in Medical, Oncology and Biotechnology startups, most often at Series D stage. Most of the 1 investments tracked by Shizune back companies in Japan. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Daniel Epstein?
For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Daniel Epstein last invest?
The most recent investment recorded for Daniel Epstein closed in Aug 2026. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
